Pharmaceutical Executive
June 01, 2012
Issue PDF
0
0
2012 Dealmakers Roundtable
June 01, 2012
Features
0
0
Early efforts in the pharma space to harness the engagement factor in game technology focused on delivering a fun experience, with a tackedon educational component. Today's games bring behavior change to the forefront, incorporating social dynamics, mobility, and increasingly sophisticated mechanics.
June 01, 2012
Features
0
0
As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.
June 01, 2012
Column
0
0
New drug indications can be a brand manager's worst nightmare or a dream come true. The difference lies in the perspective and in the branding strategy.
June 01, 2012
Column
0
0
A recent medical device controversy in France has pushed European health ministers to agree on a crisis management program for the troubled sector.
June 01, 2012
Features
0
0
Pharm Exec convened a panel of heavy hitters in business development to crack the bat on best practices in licensing and M&A for the year ahead.
June 01, 2012
Column
0
0
Understanding the differences between drug and device marketing can make or break the brand's promotional activities.
June 01, 2012
Column
0
0
No matter how the Supreme Court rules on healthcare reform, the accountable care model will stick around. To play ball with ACOs, drug companies will need to throw a different pitch.
June 01, 2012
Column
0
0
A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.
June 01, 2012
Features
0
0
Industry's ability to master the external environment depends on making the 140-character shorthand of the Twitter generation its own.
June 01, 2012
From the Editor
0
0
As the old Broadway song goes, June is busting out all over-and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous.
June 01, 2012
Column
0
0
Clayton Christensen, author of "The Innovator's Dilemma", offers to collaborate with pharma CEOs on solutions to the strategic impasse around flagging drug productivity.